Sansure Biotech Inc. (688289.SH): The human papillomavirus nucleic acid detection kit (PCR-fluorescent probe method) has been approved to increase a variety of expected uses.

Sansure Biotech Inc. (688289.SH) announced that the company's human papillomavirus nucleic acid detection kit (PCR-fluorescent probe method) recently received the "Medical Device Change Registration (Filing) Document" issued by the National Medical Products Administration. It has been officially approved for adding cervical cancer primary screening, cervical cancer combined screening, and the expected use of ASCUS population stratification.